Home/Pipeline/Orotecan™

Orotecan™

Oncology (unspecified)

Phase 1/2aActive

Key Facts

Indication

Oncology (unspecified)

Phase

Phase 1/2a

Status

Active

Company

Edison Oncology

About Edison Oncology

Edison Oncology is a private, clinical-stage biotech advancing a pipeline of novel, biomarker-targeted small molecules for cancer. Its strategy involves identifying and acquiring underdeveloped drug candidates and leveraging existing clinical data to accelerate development. The company is actively enrolling clinical trials and presenting data at major conferences, indicating progress in its lead programs. It operates with a lean, partnership-focused business model to retain meaningful development and commercial rights.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
DDX3 Inhibitor (Oncology)	Lead Discovery Siena	Discovery	Active